文献速递慢性肾脏病水电解质与酸碱

Vaptans与自愿增加饮水保护肾脏的比较

Vaptans or voluntary increased hydration to protect the kidney: how do they compare?
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本文综述了血管加压素(AVP)在慢性肾脏病中的不良作用,比较了托伐普坦(选择性V2受体拮抗剂)与自愿增加饮水两种策略。前者阻断V2R并可能通过V1aR介导PGE2增加促进利尿排钠,后者降低血浆渗透压和AVP分泌从而减少V2R、V1aR和V1bR介导的作用。作者推测药物性V2R拮抗可能获益更大,但需进一步评估托伐普坦对PGE2排泄率的影响及更低剂量的可能性。

要点

  • 托伐普坦阻断V2R后可能通过V1aR介导PGE2增加促进利尿排钠。
  • 自愿增加饮水降低AVP分泌,同时减少V2R和V1aR/V1bR介导的作用。
  • 药物性V2R拮抗可能比自愿多饮水获益更大,但需进一步验证。

核心结论

  • 药物性V2R拮抗可能比自愿增加饮水提供更大获益,但尚需评估托伐普坦对PGE2排泄率的影响及更低剂量的可能性。

研究设计与样本

  • 本文为综述,比较托伐普坦与自愿增加饮水两种降低AVP不良作用的策略。

主要发现

  • 自愿增加饮水降低血浆渗透压和AVP分泌,减少V2R及V1aR/V1bR介导的作用。
  • 选择性V2R拮抗导致液体丢失并刺激AVP分泌,增加AVP对V1aR和V1bR的影响。
  • V1aR激活诱导PGE2产生,肾内PGE2减少集合管钠水重吸收并增加肾髓质血流。
  • 非甾体抗炎药可导致显著水钠潴留并增强AVP的抗利尿作用。
  • V2R拮抗期间V1aR介导的作用可能部分解释所观察到的利尿效应。

临床怎么用

  • 临床选择托伐普坦或鼓励饮水时需考虑两者对AVP受体亚型作用及PGE2影响的差异。

局限性

  • 本文为综述,作者观点基于推测,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The adverse effects of vasopressin (AVP) in diverse forms of chronic kidney disease have been well described. They depend on the antidiuretic action of AVP mediated by V2 receptors (V2R). Tolvaptan, a selective V2R antagonist, is now largely used for the treatment of patients with autosomal dominant polycystic kidney disease. Another way to reduce the adverse effects of AVP is to reduce endogenous AVP secretion by a voluntary increase in fluid intake. These two approaches differ in several ways, including the level of thirst and AVP. With voluntary increased drinking, plasma osmolality will decline and so will AVP secretion. Thus, not only will V2R-mediated effects be reduced, but also those mediated by V1a and V1b receptors (V1aR and V1bR). In contrast, selective V2R antagonism will induce a loss of fluid that will stimulate AVP secretion and thus increase AVP's influence on V1a and V1b receptors. V1aR is expressed in the luminal side of the collecting duct (CD) and in inner medullary interstitial cells, and their activation induces the production of prostaglandins, mostly prostaglandin E2 (PGE2). Intrarenal PGE2 has been shown to reduce sodium and water reabsorption in the CD and increase blood flow in the renal medulla, both effects contributing to increase sodium and water excretion and reduce urine-concentrating activity. Conversely, non-steroidal anti-inflammatory drugs have been shown to induce significant water and sodium retention and potentiate the antidiuretic effects of AVP. Thus, during V2R antagonism, V1aR-mediated actions may be responsible for part of the diuresis observed with this drug. These V1aR-dependent effects do not take place with a voluntary increase in fluid intake. In summary, while both strategies may have beneficial effects, the information reviewed here leads us to assume that pharmacological V2R antagonism, with resulting stimulation of V1aR and increased PGE2 production, may provide greater benefit than voluntary high water intake. The influence of tolvaptan on the PGE2 excretion rate and the possibility to use somewhat lower tolvaptan doses than presently prescribed remain to be evaluated.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Bankir L, Guerrot D, Bichet DG, et al. Vaptans or voluntary increased hydration to protect the kidney: how do they compare? Nephrol Dial Transplant. 2023. PMID: 34586414. doi:10.1093/ndt/gfab278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。